Stock events for Collegium Pharmaceutical, Inc. (COLL)
Over the past six months, Collegium's stock has been impacted by several events. The company reported strong Q4 and full-year 2025 results, with product revenues and adjusted EBITDA increasing year-over-year, and reaffirmed its 2026 guidance. Collegium closed a $980 million syndicated credit facility to refinance debt and increase financial flexibility. The company reported revenues of $209.4 million in Q3 2025, up 31.4% year-on-year. Collegium announced a $25 million accelerated share repurchase program. Company insiders reduced holdings, with EVP Scott Dreyer and Director Rita J. Balice‑Gordon selling shares.
Demand Seasonality affecting Collegium Pharmaceutical, Inc.’s stock price
Demand for Collegium Pharmaceutical's products exhibits some seasonality, with seasonal volume and gross-to-net fluctuations anticipated to impact Q1 2026. The ADHD medication Jornay PM experiences a boost in performance during the "back-to-school season," suggesting higher demand during academic periods.
Overview of Collegium Pharmaceutical, Inc.’s business
Collegium Pharmaceutical, Inc. (COLL) is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and ADHD, operating within the Pharmaceuticals sector. The company's product portfolio leverages its DETERx platform technology to create abuse-deterrent, extended-release formulations. Major products include Xtampza ER, Nucynta ER and IR, Belbuca, Symproic, and Jornay PM.
COLL’s Geographic footprint
Collegium Pharmaceutical, Inc. is headquartered in Stoughton, Massachusetts, and primarily commercializes its pain portfolio and ADHD medication in the United States. The company plans to expand into international markets, particularly in Europe and Asia, by 2026.
COLL Corporate Image Assessment
Collegium Pharmaceutical has a strong market position and brand recognition in the chronic pain management sector, with brands like Xtampza ER and Jornay PM associated with quality and innovation. The DETERx platform technology provides a competitive advantage and positions the company as a leader in a niche market. Collegium has opportunities to enhance its corporate reputation by leveraging ESG initiatives. There were no specific events explicitly reported in the past year that negatively affected Collegium Pharmaceutical, Inc.'s brand reputation.
Ownership
A significant portion of Collegium Pharmaceutical, Inc.'s stock is held by institutional investors, including BlackRock, Inc., The Vanguard Group, Inc., and iShares. The largest individual shareholder is David Hirsch, owning 6.44 million shares, representing 20.28% of the company.
